These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32760020)

  • 21. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
    Gao L; Moodie M; Li SC
    Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Total Events With Icosapent Ethyl: Can We Reduce It?
    Granger CB; Nelson AJ; Pagidipati NJ
    J Am Coll Cardiol; 2019 Jun; 73(22):2803-2805. PubMed ID: 31171085
    [No Abstract]   [Full Text] [Related]  

  • 24. Federal court invalidates Sanofi's Plavix patent for alleged insufficiency and obviousness.
    Folkins P
    Health Law Can; 2012 Feb; 32(3):46-8. PubMed ID: 22458154
    [No Abstract]   [Full Text] [Related]  

  • 25. The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction.
    Wang X; Verma S; Mason RP; Bhatt DL
    Curr Diab Rep; 2020 Oct; 20(11):65. PubMed ID: 33095318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
    Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
    Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Aug; 74(8):1159-1161. PubMed ID: 31439224
    [No Abstract]   [Full Text] [Related]  

  • 28. Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke.
    Myran L; Nguyen TN
    Am Fam Physician; 2021 Jan; 103(2):117-118. PubMed ID: 33448769
    [No Abstract]   [Full Text] [Related]  

  • 29. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
    Jia X; Akeroyd JM; Nasir K; Nambi V; Ballantyne CM; Petersen LA; Virani SS
    Circulation; 2019 Mar; 139(10):1341-1343. PubMed ID: 30865483
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypertriglyceridaemia - REDUCE-IT with icosapent ethyl.
    Lim GB
    Nat Rev Cardiol; 2019 Jan; 16(1):1. PubMed ID: 30479386
    [No Abstract]   [Full Text] [Related]  

  • 31. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Risk Reduction with Icosapent Ethyl.
    Borghi C; Fogacci F; Cicero AFG
    N Engl J Med; 2019 Apr; 380(17):1678. PubMed ID: 31018076
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular Risk Reduction with Icosapent Ethyl.
    Chan LN
    N Engl J Med; 2019 Apr; 380(17):1677. PubMed ID: 31018075
    [No Abstract]   [Full Text] [Related]  

  • 34. Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.
    Bhatt DL; Steg PG; Miller M
    N Engl J Med; 2019 Apr; 380(17):1678. PubMed ID: 31018077
    [No Abstract]   [Full Text] [Related]  

  • 35. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial commentary: Icosapent ethyl in the treatment and prevention of cardiovascular disease.
    Gitin A; Hennekens CH
    Trends Cardiovasc Med; 2020 Apr; 30(3):158-159. PubMed ID: 31147256
    [No Abstract]   [Full Text] [Related]  

  • 37. Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients.
    Boden WE; Andersson C
    J Am Coll Cardiol; 2022 May; 79(17):1672-1674. PubMed ID: 35483754
    [No Abstract]   [Full Text] [Related]  

  • 38. Triglyceride lowering drugs: not just icosapent ethyl.
    Spence JD
    Eur Heart J; 2020 Apr; 41(15):1520. PubMed ID: 32154875
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular risk reduction with icosapent ethyl.
    Patel PN; Patel SM; Bhatt DL
    Curr Opin Cardiol; 2019 Nov; 34(6):721-727. PubMed ID: 31464773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.